Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Acute ischemic stroke (AIS) occurs when blood flow through a brain artery is obstructed by a clot, which is a thickened mass of blood. Clots are classified as either thrombotic or embolic depending on where they form in the body. The most common type of stroke is a thrombotic stroke, which occurs when a clot forms within a brain artery. An embolic stroke occurs when a clot or small piece of plaque (fatty deposit) breaks off from another part of the body, such as the heart, and travels through the bloodstream before becoming lodged in a narrower vessel in the brain. Large vessel occlusion (LVO) is responsible for nearly half of all acute ischemic strokes. LVO is the most serious and debilitating type of stroke because the clot blocks large arteries and prevents blood flow to essential parts of the brain.
The global acute ischemic stroke (AIS) market is estimated to be valued at US$ 8,517.0 million in 2021 and is expected to increase to US$ 11,185.3 Mn by 2028, witnessing a CAGR of 4.0% over the forecast period (2021-2028).
Figure 1. Global Acute Ischemic Stroke (AIS) Market Value (US$ Mn) & Y-o-Y Growth (%)
Increasing prevalence of ischemic stroke globally is expected to drive the growth of the global acute ischemic stroke (AIS) market.
For instance, as per the 2021 Heart Disease & Stroke Statistical Update Fact Sheet provided by the American Heart Association, the global prevalence of stroke in 2019 was 101.5 million people, while that of ischemic stroke was 77.2 million. Overall, age-standardized stroke prevalence rate in 2019 was highest in Oceania, Southeast Asia, North Africa, and the Middle East, as well as East Asia. Countries in parts of North Africa and the Middle East, Southern sub-Saharan Africa, high-income countries in North America and Southeast Asia had the highest ischemic stroke prevalence rate. Furthermore, in 2019, there were 6.6 million deaths worldwide due to cerebrovascular diseases. In 2019, a total of 3.3 million people worldwide died from ischemic stroke, 2.9 million died from intracerebral hemorrhage, and 0.4 million died from subarachnoid hemorrhage.
Acute Ischemic Stroke (AIS) Market Report Coverage
||Market Size in 2021:
||US$ 8,517.0 Mn
|Historical Data for:
||2017 to 2020
||2021 to 2028
|Forecast Period 2021 to 2028 CAGR:
||2028 Value Projection:
||US$ 11,185.3 Mn
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
- Middle East: GCC Countries, Israel, and Rest of Middle East
- Africa: South Africa, North Africa, and Central Africa
- By Therapeutics: Tissue Plasminogen Activator, Anticoagulant, Antiplatelet, Antihypertensive
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
F. Hoffmann-La Roche AG, Boehringer Ingelheim, Bayer AG, Pfizer Inc., Biogen, Daiichi Sankyo, Bristol-Myers Squibb, Johnson & Johnson, AstraZeneca, SanBio and Athersys Inc.
- The rising prevalence of acute ischemic stroke cases
- Technological advancements in surgical procedures
- Rising geriatric population
- Increased demand for minimally invasive procedures
|Restraints & Challenges:
- High cost of treatment
- Lack of transparent reimbursement policies
Figure 2. Global Acute Ischemic Stroke (AIS) Market Share (%), By Region, 2021
Global Acute Ischemic Stroke (AIS) Market – Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread over 100 countries across the globe. The coronavirus (COVID-19) pandemic and lockdown in various countries across the globe have impacted the financial status of businesses in all sectors. Private healthcare sector is one of the sectors, which is majorly impacted by the COVID-19 pandemic.
In the context of the coronavirus (COVID-19) global pandemic caused by SARS-CoV-2, a possible link between this disease and stroke has been proposed. Between March 24, 2020 and July 17, 2020, PCR-confirmed COVID-19 patients with ischemic stroke were admitted to an academic health system in metropolitan Atlanta, Georgia (U.S.). 13 (2.5%) of 396 ischemic stroke patients admitted during this study period were also diagnosed with COVID-19. Each of the 13 patients had at least one stroke-related co-morbidity. The most common type of ischemic stroke was embolic, with four cases explained by atrial fibrillation. During the study period, COVID-19 patients had a significantly higher rate of cryptogenic stroke than non-COVID-19 patients.
Global Acute Ischemic Stroke (AIS) Market: Restraint
High cost of treatment and lack of transparent reimbursement policies is expected to restrain the market growth over the forecast period. For instance, according to an article published by National Center for Biotechnology Information (NCBI), published in August 2018, the average in-hospital cost per acute stroke patient was approximately US$ 6961 ± 15,663 in Lebanon. Cost determinants were length of hospital stay, length of intensive care unit stay, stroke type, stroke severity, modified Rankin scale, third-party payers, operations, and infectious complications.
Major players operating in the global acute ischemic stroke (AIS) market include F. Hoffmann-La Roche AG, Boehringer Ingelheim, Bayer AG, Pfizer Inc., Biogen, Daiichi Sankyo, Bristol-Myers Squibb, Johnson & Johnson, AstraZeneca, SanBio and Athersys Inc.